08:00 | Registration | |||
09:20 | Inauguration | |||
09:30 |
| |||
10:15 | Coffee Break and Networking in Exhibition Hall | |||
10:35 |
| |||
11:15 | Challenges in ADME and Metabolomics | |||
11:45 | Roadmaps to Success in Novel Drug Discovery and Development through PADMET Profiling | |||
12:15 | Recent Trends in Development on LCMS/MS Enabling Unique Workflow in Metabolite Identification | |||
12:45 | Lunch in the Hall | |||
13:45 | Technology Spotlight: | |||
14:00 | ADME, Dissolution and Bioavailability: Establishing a Relationship | |||
14:30 |
| |||
15:10 | Coffee Break and Networking in Exhibition Hall | |||
15:30 | Preclinical Formulations for Early Discovery Invivo studies | |||
16:30 | Atrovastatin Causing Peripheral Neuropathy - Is It a Signal? | |||
17:00 | End of the Day | |||
18:00 | Drink Reception and Networking |
09:00 |
| |||
09:40 | Integrating In Vitro and In Silico Approaches for Mechanistic Toxicology | |||
10:10 | Coffee Break and Networking in Exhibition Hall | |||
10:30 | Therapeutic Drug Monitoring and Drug Safety | |||
11:00 | Newer Strategies in Drug Safety Research: A Translational Approach | |||
11:30 | Recent Amendments to the Indian Clinical Trial Regulations and its Impact on the Clinical Research Industry | |||
12:00 | Bioavailability and Bioequivalence Pharmacokinetic Studies: An FDA Regulatory Overview | |||
12:30 | Issues and Challenges in Clinical Pharmacokinetic Evaluation of a New Drug Molecule | |||
13:00 | Poster Session | |||
13:20 | Lunch in the Hall | |||
14:20 | Personalized Medicine: The Leading Edge in Human Health | |||
14:50 | Genotoxicity Testing in Drug Safety Evaluation: Models, Bioassays and End-points for Regulatory Consideration | |||
15:20 | Coffee Break and Networking in Exhibition Hall | |||
15:40 | Preclinical Evaluation of Drug Safety | |||
16:10 | Bioinformatics Concept, Methods & Techniques for ADME, Toxicology & Drug Designing | |||
16:30 | Panel Discussion: Pre-clinical and Clinical Outsourcing- Current Indian Scenario | |||
17:00 | End of the Conference |